Compare IDEXX Laboratories, Inc. (IDXX) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Progressive Corp — how do they compare? IDEXX Laboratories, Inc. trades at $554.89 (market cap $44.48B), while Progressive Corp trades at $206.84 (market cap $123.39B). The key difference: Progressive Corp is far larger — about 2.8× IDEXX Laboratories, Inc.'s market cap, and Progressive Corp pays a 6.55% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PGR | |
|---|---|---|
Market Cap | $44.48B | $123.39B |
Sector | Health | Financials |
52-Week High | $766.68 | $252.68 |
52-Week Low | $520.87 | $190.40 |
Enterprise Value | $45.38B | $131.61B |
Dividend Yield | — | 6.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
PGR trades at $211.22, up 1.57% over 24 hours, with a bearish technical signal but neutral oscillators. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin expanding to 12.9%. Recent Q2 2026 earnings matched expectations at $4.64 EPS. Analyst consensus price target is $234.56 with 37% buy ratings, though technical resistance looms near $212.
Outlook remains cautiously optimistic given Progressive's earnings consistency and valuation at 10.43 P/E, but risks include competitive pressures and potential earnings volatility. The stock offers value with dividend yield support, though investors should monitor premium growth sustainability amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
